Hair loss treatments have been available for decades, and for more than 25 years, finasteride has remained the first-line oral treatment for androgenetic alopecia. Approved for male pattern baldness in the late 1990s, it has consistently been used as a primary DHT blocker for hair loss and continues to play a significant role in the medical management of baldness.

With the emergence of clascoterone as a hair loss treatment, a new discussion has started in both clinical and patient settings:

• Can clascoterone replace finasteride?
• Is this topical anti-androgen for hair loss more effective than an oral DHT blocker?

At AK Clinics, finasteride is recommended under the supervision of our expert dermatologists for carefully selected early-to-moderate cases where follicle preservation is possible. Clascoterone, on the other hand, is still under clinical trial evaluation for hair loss and is not yet an established replacement. The growing comparison between the two reflects the broader debate between oral and topical DHT-blocking approaches.

In this blog, we break down finasteride vs clascoterone for male pattern baldness, examine current clinical trial data, discuss finasteride side effects, and explore whether clascoterone can truly serve as a reliable alternative to finasteride in modern androgenetic alopecia treatment.

What Is Clascoterone and How Does It Work?

Can a topical solution change the way we approach androgenetic alopecia treatment? That question has drawn growing attention to clascoterone hair-loss therapy, particularly the 5% topical solution currently being studied for male pattern baldness.

Clascoterone is a topical anti-androgen that was first approved for acne treatment and is now being evaluated for its potential role in hair loss. Unlike oral medications, clascoterone 5% solution is applied directly to the scalp, targeting the affected area rather than acting systemically throughout the body.

Clascoterone works at the receptor level rather than reducing hormone production. It:

• Blocks androgen receptors at the scalp
• Prevents DHT from binding to hair follicles
• Slows follicle miniaturisation
• Acts locally without lowering systemic DHT

Researchers are examining its use in androgenetic alopecia because it blocks androgen receptors at the scalp level. At present, clascoterone 5% solution is still in clinical trials for hair loss and has not yet received approval as a standard first-line treatment.

What Is Finasteride and How Does It Work?

Finasteride is an FDA-approved oral medication used to treat androgenetic alopecia (male pattern baldness). It works as a DHT blocker for hair loss and is commonly prescribed as part of the medical management of baldness in suitable patients.

Finasteride works by inhibiting the 5-alpha reductase enzyme. This enzyme converts testosterone into dihydrotestosterone (DHT), the hormone responsible for follicle miniaturisation in male pattern baldness. By lowering DHT levels in the body, finasteride:

• Reduces DHT production
• Slows follicle miniaturisation
• Decreases ongoing hair thinning
• Helps preserve existing hair

Because it reduces DHT systemically, finasteride acts throughout the body rather than only at the scalp. As a result of this systemic action, a small percentage of patients over the years have reported side effects such as reduced libido or erectile dysfunction, which is why medical supervision and proper counselling are important before starting treatment.

Clascoterone vs Finasteride: Oral vs Topical DHT Blocker Comparison

When comparing clascoterone vs finasteride, the key difference lies in how each treatment targets DHT. Both are used in androgenetic alopecia treatment, but they control DHT in different ways. Understanding this distinction is essential when evaluating oral vs topical DHT-blocking approaches for long-term hair loss management.

In clinics, dermatologists decide which treatment is appropriate based on the patient’s stage of hair loss, follicle condition, hair loss progression, and other clinical factors.

In the evolving clascoterone vs finasteride discussion, clascoterone may shape the future of topical anti-androgen therapy, pending stronger long-term clinical validation under the supervision of dermatologists.

Medical Usage Before and After Hair Transplant Surgery

A hair transplant redistributes hair into areas where follicles are no longer viable, but it does not stop the underlying DHT-driven process of androgenetic alopecia. For this reason, medical therapy remains an important part of long-term hair loss management, both before and after surgery.

Before Hair Transplant Surgery (Pre-Op Care)

Finasteride may help by:

• Reducing systemic DHT levels
• Slowing further miniaturisation
• Stabilising ongoing hair loss

Clascoterone may help by:

• Blocking DHT activity at the scalp
• Supporting control of early thinning areas
• Offering a topical option for patients cautious about oral therapy

After Hair Transplant Surgery (Post-Op Care)

Finasteride may help by:

• Maintaining hair transplant results
• Protecting non-transplanted follicles
• Reducing future progression

Clascoterone may help by:

• Supporting scalp-level DHT control
• Protecting the surrounding native hair
• Serving as a topical maintenance option

Can Clascoterone Replace Finasteride?

Clascoterone (in its 5% solution) is a novel topical androgen receptor inhibitor designed to act locally on the scalp. Unlike oral therapies that reduce systemic DHT levels, clascoterone blocks androgen receptors directly within the hair follicle environment. This localised mechanism is what differentiates it in the evolving landscape of advanced hair loss treatments.

Clascoterone should therefore be viewed as an emerging topical anti-androgen for hair loss that may expand treatment options, particularly for patients who prefer to avoid oral medications, including those concerned about the potential sexual side effects reported with systemic DHT reduction from oral finasteride. At present, it should be considered an emerging therapy rather than a confirmed substitute.

If you are weighing topical against oral options more broadly, our guide on minoxidil vs DHT blockers explains how growth-stimulating and DHT-controlling treatments differ, and our overview of DHT blocker medicines for hair loss compares finasteride, dutasteride, and topical options in more detail.

Summary: Is Topical Anti-Androgen the Future?

Topical anti-androgen therapy such as clascoterone represents a meaningful shift in androgenetic alopecia treatment. In Phase 3 clinical trials (SCALP 1 and SCALP 2) involving 1,465 men, clascoterone 5% solution demonstrated a statistically significant improvement in hair growth compared with placebo, with primarily mild local side effects reported.

With the global hair loss treatment products market projected to grow steadily through 2032, demand for non-oral and scalp-targeted hair loss therapies is expected to increase. If approved by regulatory authorities, clascoterone could be positioned as a first-line topical solution within this expanding androgenetic alopecia treatment landscape.

Ultimately, treatment decisions are customised based on a dermatologist’s medical assessment of the patient. At AK Clinics, our experienced dermatologists examine the stage of hair loss, scalp condition, and surgical suitability before recommending any medical or surgical hair restoration plan.

Frequently Asked Questions